Endonovo Therapeutics announced the delivery of SofPulse® evaluation units to all thirty-two National Football League (“NFL”) teams.
Alan Collier, CEO of Endonovo Therapeutics stated, “With injuries affecting the NFL more than any other professional sports league, we are pleased to support the health of NFL players by providing SofPulse® evaluation units to all NFL teams. The SofPulse® device is clinically proven to reduce post-operative pain, swelling and need for opioids. Endonovo is committed to helping NFL players get back on the field faster when recovering from medical procedures caused by injuries.
About Endonovo Therapeutics Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals® therapeutic devices. The Company’s current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome and multiple sclerosis.
The Company’s non-invasive Electroceutical® therapeutic device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceuticals® therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company’s non-invasive, wearable Electroceuticals® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.
For more information about Ordering or Additional Details. Please contact Herzog Surgical at 800-637-1288 or email us at email@example.com
Reference: See Full Press Release Here.